1479P Ultra-sensitive Circulating Tumor DNA (ctdna) Assay Distinguishes Partial Response (PR) and Complete Response (CR) with Immunotherapy in Metastatic Renal Cell Carcinoma (Mrcc)

A. Chehrazi-Raffle, R. Muddasani,N. Dizman,J. Hsu,L. Meza,Z. B. Zengin,J. Malhotra,N. Chawla,Y. M. Lyou,T. Dorff, T. Contente-Cuomo, D. Dinwiddie,B. McDonald,J. Trent,M. Murtaza,S. K. Pal

Annals of oncology（2022）

引用 0|浏览8

暂无评分

摘要

ctDNA is validated across multiple indications for identification of actionable mutations and detection of minimal residual disease. We evaluated if TARgeted DIgital Sequencing (TARDIS) may distinguish PR from CR with in mRCC patients (pts) receiving immune checkpoint inhibitor (ICI) therapy.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要